Revolution Medicines, Inc.
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
Last updated:
Abstract:
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
Status:
Grant
Type:
Utility
Filling date:
26 Mar 2020
Issue date:
20 Apr 2021